SYNAGEVA BIOPHARMA CORP — key financial figures for fiscal year 2014 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2014)

$6.5M

Net Income/Loss (FY2014)

-$192.6M

Total Assets (FY2014)

$504.2M

Total Equity (FY2014)

$473.2M

Cash Flows from Operating Activities (FY2014)

-$150.1M

Source: SYNAGEVA BIOPHARMA CORP 10-K filing (FY2014). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.